GSK2798745

Unknown / undisclosed

DiscontinuedTRPV4No recent registered activity
Discontinuedsponsor decision

Evidence outlook · program status

Discontinued (2022-04), after a negative readout

GSK2798745 is GSK's TRPV4 channel blocker, taken through heart failure, chronic cough and diabetic macular edema. Its last study, the diabetic macular oedema Phase 1, was terminated for futility on 2022-04-11; the chronic cough study NCT03372603 had already been terminated for lack of efficacy and no GSK2798745 study has started since. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.

Featured evidence outside this drug's tracked markets:NCT04292912 · Macular Edema · Phase 1 · Weak signal

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (2)
Phase 1/2 (1)
Other / comorbidity
NCT03372603 · GlaxoSmithKline
2018-04-05 – 2018-10-08 · Cough
What this study did
Phase 1 (3)
Other / comorbidity
NCT04292912 · GlaxoSmithKline
2020-09-07 – 2022-04-11 · Macular Edema
What this study did
NCT03511105 · GlaxoSmithKline
2018-06-25 – 2018-12-18 · Healthy Volunteers
What this study did
NCT02925546 · GlaxoSmithKline
2016-10 – 2016-12 · Heart Failure, Congestive
What this study did

Competitive landscape

No competitors sharing a mechanism or indication in the current universe.

Upcoming events

No upcoming readouts on record for this asset.